Stem cell transplantation - Clinical: Other Complications
Yaqiong Tang, Jia Chen, Tiantian Chu, et al.
The authors of the abstract conclude:
Decitabine effectively facilitated platelet recovery in HCT-RPIT patients, presumably by promoting the repair and reconstitution of megakaryocytes and marrow endothelial cells.
————————————————————————————————————————————————————————
Masamichi Isobe, Takaaki Konuma, Masayoshi Masuko, et al.
The authors of the abstract conclude:
Although the risks of engraftment failure and early NRM were not low, single CBT could be effective treatment option for AML patients aged 60 years or older.
————————————————————————————————————————————————————————
Alessandro Rambaldi, Mark Smith, Steve Whitaker, Samer Khaled
The authors of the abstract conclude:
In this trial, most narsoplimab-treated patients achieved a complete response with a significant improvement in laboratory markers and in clinical status. No safety signal was observed.
————————————————————————————————————————————————————————
xing-ye meng, hai-xia fu, xiao liu, et al.
The authors of the abstract conclude:
CMV viral load and refractory CMV infection played an important role in CMV diseases. The mortality after the diagnosis of CMVP, Di-CMVD and CMVE was higher than that of CMVG and CMVR. Besides, CMVP, CMVR and CMVE were associated with increased mortality independently.
————————————————————————————————————————————————————————
Antonio Pierini, Loredana Ruggeri, Carotti Alessandra, et al.
The authors of the abstract conclude:
A haploidentical transplantation protocol that combined an age-adjusted myeloablative conditioning regimen with Treg/Tcon adoptive immunotherapy provided an unprecedented 78% chronic GvHD/relapse-free survival in 50 AML patients despite 31 were 50 to 65 years-old.